Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6676 to 6690 of 8904 results

  1. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  2. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  3. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  4. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  5. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  6. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  7. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  8. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    In development Reference number: GID-TA11442 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    In development Reference number: GID-TA11466 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development Reference number: GID-TA10607 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued Reference number: GID-TA11024

    Technology appraisal guidance
    Discontinued

  13. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

    Technology appraisal guidance
    Discontinued

  14. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

    Technology appraisal guidance
    Discontinued

  15. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

    Technology appraisal guidance
    Discontinued